族群差异对他汀类药物降脂疗效影响
The Impact of Ethnic Differences on the Lipid-Lowering Efficacy of Statins
DOI: 10.12677/acm.2026.1631020, PDF,   
作者: 费华彬*, 彭新元, 毛艺敏：吉首大学医学院，湖南 吉首；谷祥任：张家界市人民医院心血管内科，湖南 张家界
关键词: 他汀类药物；疗效差异；个体化治疗；心血管疾病；降脂；基因多态性；Statins； Efficacy Differences； Personalized Treatment； Cardiovascular Diseases； Lipid-Lowering； Genetic Polymorphism
摘要: 冠状动脉粥样硬化性心脏病(Coronary Atherosclerotic Heart Disease, CHD)是由于冠状动脉粥样硬化使管腔狭窄或阻塞导致心肌缺血、低氧而引起的心脏病，该疾病众多危险因素中血脂占据了至关重要的作用。他汀类药物作为降脂治疗的核心，其在降低胆固醇水平和预防心血管疾病方面的显著疗效已获得普遍认同，然而，不同族群患者对治疗的效果却存在差异。本文系统回顾他汀类药物的降脂机制及其影响因素，为在我国多族群背景下实现更精准、个体化的降脂治疗策略提供理论依据。
Abstract: Coronary Atherosclerotic Heart Disease (CHD) is a heart disease caused by myocardial ischemia and hypoxia caused by narrowing or blocking of the lumen by coronary atherosclerosis. As the core of lipid-lowering therapy, statins have been widely recognized for their significant efficacy in lowering cholesterol levels and preventing cardiovascular disease, however, the efficacy of treatment varies among different ethnic groups. This article systematically reviews the lipid-lowering mechanism and influencing factors of statins, so as to provide a theoretical basis for achieving more precise and individualized lipid-lowering treatment strategies in the context of multi-ethnic groups in China.
文章引用：费华彬, 彭新元, 毛艺敏, 谷祥任. 族群差异对他汀类药物降脂疗效影响[J]. 临床医学进展, 2026, 16(3): 2258-2264. https://doi.org/10.12677/acm.2026.1631020

参考文献

[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志, 2023, 38(6): 583-612.
[2] Ference, B.A., Ginsberg, H.N., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. a Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472. [Google Scholar] [CrossRef] [PubMed]
[3] 中国血脂管理指南(2023年)中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023) [J]. 中国循环杂志, 2023, 38(3): 237-269.
[4] Frank, D.A., Johnson, A.E., Hausmann, L.R.M., Gellad, W.F., Roberts, E.T. and Vajravelu, R.K. (2023) Disparities in Guideline-Recommended Statin Use for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Gender: A Nationally Representative Cross-Sectional Analysis of Adults in the United States. Annals of Internal Medicine, 176, 1057-1066. [Google Scholar] [CrossRef] [PubMed]
[5] Gebremichael, L.G., Suppiah, V., Wiese, M.D., Mackenzie, L., Phillips, C., Williams, D.B., et al. (2021) Efficacy and Safety of Statins in Ethnic Differences: A Lesson for Application in Indigenous Australian Patient Care. Pharmacogenomics, 22, 553-571. [Google Scholar] [CrossRef] [PubMed]
[6] 张硕杰, 王辉, 张彤彤, 等. HMGCR表达及活性调控的研究进展[J]. 中国细胞生物学学报, 2023, 45(6): 990-996.
[7] Tobert, J.A. (2003) Lovastatin and Beyond: The History of the HMG-CoA Reductase Inhibitors. Nature Reviews Drug Discovery, 2, 517-526. [Google Scholar] [CrossRef] [PubMed]
[8] Magni, P., Macchi, C., Morlotti, B., Sirtori, C.R. and Ruscica, M. (2015) Risk Identification and Possible Countermeasures for Muscle Adverse Effects during Statin Therapy. European Journal of Internal Medicine, 26, 82-88. [Google Scholar] [CrossRef] [PubMed]
[9] Haynes, R., Lewis, D., Emberson, J., et al. (2014) Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology, 25, 1825-1833.
[10] 李涛. 他汀类药物临床多效性研究进展[J]. 临床合理用药杂, 2021, 14(23): 179-181.
[11] 孟婷婷, 耿德胜. 他汀类药物在缺血性脑血管病二级预防中的应用效果及其影响因素[J]. 医学临床研究, 2024, 41(7): 1061-1063, 1067.
[12] 许娇娇, 郭珊珊, 宗传杰, 等. 不同基因多态性对他汀类药物影响的研究进展[J]. 现代药物与临床, 2022, 37(11): 2647-2652.
[13] Lee, E., Ryan, S., Birmingham, B., Zalikowski, J., March, R., Ambrose, H., et al. (2005) Rosuvastatin Pharmacokinetics and Pharmacogenetics in White and Asian Subjects Residing in the Same Environment. Clinical Pharmacology & Therapeutics, 78, 330-341. [Google Scholar] [CrossRef] [PubMed]
[14] Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., et al. (2006) Primary Prevention of Cardiovascular Disease with Pravastatin in Japan (MEGA Study): A Prospective Randomised Controlled Trial. The Lancet, 368, 1155-1163. [Google Scholar] [CrossRef] [PubMed]
[15] Li, Y., Feng, Q., Gao, W., Zhang, X., Huang, Y. and Chen, Y. (2015) The Difference between Asian and Western in the Effect of LDL-C Lowering Therapy on Coronary Atherosclerotic Plaque: A Meta-Analysis Report. BMC Cardiovascular Disorders, 15, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[16] 罗思富, 金梦龙, 苏比努尔∙居热提, 等. 不同民族动脉粥样硬化性心血管疾病患者中等剂量他汀类药物治疗的疗效差异研究[J]. 中国全科医学, 2024, 27(36): 4522-4526, 4533.
[17] Cooper‐DeHoff, R.M., Niemi, M., Ramsey, L.B., Luzum, J.A., Tarkiainen, E.K., Straka, R.J., et al. (2022) The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 Genotypes and Statin‐associated Musculoskeletal Symptoms. Clinical Pharmacology & Therapeutics, 111, 1007-1021. [Google Scholar] [CrossRef] [PubMed]
[18] 蔡晓彤, 游璎琦, 杨欣. 他汀类药物个体化用药研究进展[J]. 实用药物与临床, 2021, 24(10): 950-955.
[19] 中国中西医结合学会检验医学专业委员会, 浙江省免疫学会临床免疫诊断专业委员会, 浙江省药理学会治疗药物监测研究专业委员会, 王建安, 杨曦明, 戴海斌, 陶志华, 杨明东, 段秀枝. SLCO1B1和ApoE基因多态性检测与他汀类药物临床应用专家共识[J]. 中华检验医学杂志, 2023, 46(7): 672-680.
[20] 张琳, 杨爽, 张素雅, 等. 西北地区冠心病患者ApoE基因多态性分布研究以及对他汀类药物使用的指导意义[J]. 中国实验诊断学, 2024, 28(6): 669-673.
[21] 韩勇军, 张亚威, 高伟, 等. 郑州地区SLCO1B1和ApoE基因多态性分布情况[J]. 心脏杂志, 2022, 34(1): 44-48.
[22] 杜海燕, 缪阳, 张婷, 等. ApoE基因多态性对瑞舒伐他汀疗效的影响[J]. 药学与临床研究, 2021, 29(1): 47-49.
[23] Miao, G., Zhuo, D., Han, X., Yao, W., Liu, C., Liu, H., et al. (2023) From Degenerative Disease to Malignant Tumors: Insight to the Function of ApoE. Biomedicine & Pharmacotherapy, 158, Article ID: 114127. [Google Scholar] [CrossRef] [PubMed]
[24] 梁浩林, 陈耿基, 肖佳海, 等. ApoE结构和功能及其在心血管疾病中的作用[J/OL]. 生命科学: 1-19.
http://kns.cnki.net/kcms/detail/31.1600.Q.20250605.1607.002.html, 2025-06-16.
[25] Zhou, X., Fu, A.K. and Ip, N.Y. (2021) APOE Signaling in Neurodegenerative Diseases: An Integrative Approach Targeting APOE Coding and Noncoding Variants for Disease Intervention. Current Opinion in Neurobiology, 69, 58-67. [Google Scholar] [CrossRef] [PubMed]
[26] Lanfranco, M.F., Ng, C.A. and Rebeck, G.W. (2020) ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease. International Journal of Molecular Sciences, 21, Article 6336. [Google Scholar] [CrossRef] [PubMed]
[27] 李洁, 程筱雯, 许翔, 等. 安徽汉族心脑血管疾病患者SLCO1B1和ApoE基因多态性分析[J]. 安徽医科大学学报, 2025, 60(4): 619-623.
[28] 刘佳, 尤佳, 朱华, 等. ApoE和SLCO1B1基因多态性对高脂血症患者降脂治疗的效果影响[J]. 中国医药导报, 2023, 20(35): 19-23.
[29] De Leeuw, S.M., Kirschner, A.W.T., Lindner, K., et al. (2022) APOE2, E3, and E4 Differentially Modulate Cellular Homeostasis, Cholesterol Metabolism, and Inflammatory Response in Isogenic iPSC-Derived Astrocytes. Stem Cell Reports, 17, 110-126.
[30] 蒋琳芝, 李雷, 杨丹丹, 等. 依洛尤单抗对不同载脂蛋白E基因型动脉硬化性心血管疾病患者血脂的影响[J]. 中国新药与临床杂志, 2023, 42(10): 659-663.
[31] Liu, J., Liu, X., Chen, S., Zhang, Y., Cai, L., Yang, M., et al. (2017) SLCO1B1 521T > C Polymorphism Associated with Rosuvastatin-Induced Myotoxicity in Chinese Coronary Artery Disease Patients: A Nested Case-Control Study. European Journal of Clinical Pharmacology, 73, 1409-1416. [Google Scholar] [CrossRef] [PubMed]
[32] Niemi, M., Pasanen, M.K. and Neuvonen, P.J. (2011) Organic Anion Transporting Polypeptide 1B1: A Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 63, 157-181. [Google Scholar] [CrossRef] [PubMed]
[33] 李若茗, 向倩, 胡琨, 等. SLCO1B1基因多态性的辛伐他汀个体化用药临床研究分析[J]. 中国临床药理学杂志, 2022, 38(14): 1688-1691.
[34] 智丽霞, 王康, 杨慧宇. SLCO1B1基因多态性分析及其临床意义[J]. 中国医药, 2022, 17(6): 899-902.
[35] 李静, 陈雯雯, 袁圆, 等. SLCO1B1388A > G与521T > C基因多态性对不同中等强度他汀降脂疗效与安全性的影响[J]. 中国药学杂志, 2025, 60(4): 412-421.
[36] Xiang, Q., Chen, S., Ma, L., Hu, K., Zhang, Z., Mu, G., et al. (2018) Association between SLCO1B1 T521C Polymorphism and Risk of Statin-Induced Myopathy: A Meta-Analysis. The Pharmacogenomics Journal, 18, 721-729. [Google Scholar] [CrossRef] [PubMed]
[37] Wu, X., Gong, C., Weinstock, J., Cheng, J., Hu, S., Venners, S.A., et al. (2018) Associations of the SLCO1B1 Polymorphisms with Hepatic Function, Baseline Lipid Levels, and Lipid-Lowering Response to Simvastatin in Patients with Hyperlipidemia. Clinical and Applied Thrombosis/Hemostasis, 24, 240S-247S. [Google Scholar] [CrossRef] [PubMed]

为你推荐